Projects funded by the NCN
Towards innovative strategy for treatment of Alzheimer's Disease via dual inhibition of receptor 5-HT6 and kinase CDK5.
2020/37/N/NZ7/02792
Keywords:
Alzheimer's Disease 5-HT6 kinase CDK5
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- ST4_8: Organic chemistry
- NZ2_7: Bioinformatics
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Jagielloński, Collegium Medicum
woj.
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 19 - announced on 2020-03-16
Amount awarded: 210 000 PLN
Project start date (Y-m-d): 2021-02-01
Project end date (Y-m-d): 2025-01-31
Project duration:: 48 months (the same as in the proposal)
Project status: Project completed
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agentsAuthors:Sylwia Sudoł-Tałaj, Katarzyna Kucwaj-Brysz, Sabina Podlewska, Rafał Kurczab, Grzegorz Satała, Barbara Mordyl, Monika Głuch-Lutwin, Natalia Wilczyńska-Zawal, Magdalena Jastrzębska-Więsek, Kinga Czarnota-Łydka, Kinga Kurowska, Monika Kubacka, Ewa Żesławska, Wojciech Nitek, Agnieszka Olejarz-Maciej, Agata Doroz-Płonka, Anna Partyka, Gniewomir Latacz, Anna Wesołowska, Jadwiga HandzlikAcademic press:European Journal of Medicinal Chemistry (rok: 2023, tom: 260, strony: 115756), Wydawca: ScienceDirectStatus:PublishedDOI:10.1016/j.ejmech.2023.115756 - link to the publication